Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment

• Status: Completed
• Trial end date: 2017-10-02
• Target enrollment: 0
• Participant gender: All

Summary

Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an exceptional ability to stimulate different characteristics of mesenchymale cells to osseous cells. Local application of BMP results in an increase of osseous tissue regardless of the location of the growth factor.

5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and improve clinical results when autologous bone graft is reduced or removed.

The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace autologous bone graft in order to stimulating ossification during transplantation of osseous tissue.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northern Orthopaedic Division, Denmark
• Collaborators: Center for Clinical and Basic Research (CCBR A/S).; Medtronic

Criteria

Inclusion Criteria:

• Hospitalised for autologous bone graft based on Ilizarow treatment.

• Age between 20 and 70 years.

Exclusion Criteria:

• Rheumatoid osteoarthritis

• Malignant disease

• Current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea)

• Pregnancy

• Abuse of drugs and alcohol

• Need of long-term NSAID treatment

• Breastfeeding women